Overactive bladder, inflammation and urinary tract infection: pathogenetic parallels

Abstract

The review is devoted to modern ideas about the role of inflammation and urinary tract infection in the pathogenesis of overactive bladder. The molecular mechanisms of the mechanosensory function of the urothelium and the influence of bacterial colonization of the urothelium on it are described in detail. It has been shown that infectious inflammation, even in the absence of clinical symptoms, enhances the urothelial response to stretching and increases the excitability of afferent nerves. Bladder hypersensitivity and increased detrusor activity are pathogenetic basis for the development of overactive bladder. Data on the relationship between urinary infection and refractory overactive bladder are presented. The feasibility of conducting extended microbiological studies in patients with overactive bladder , especially when standard therapy is ineffective, has been demonstrated. A pathogenetic rationale for prescribing anti-inflammatory and immunoactive drugs to patients with overactive bladder is presented.

Keywords

overactive bladder / hypersensory bladder / bladder outlet obstruction / detrusor overactivity / urinary tract infection / urothelium

References

[1] Abrams P, Cardozo L, Fall M, et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178. doi: 10.1002/nau.10052

[2] Abrams P., Cardozo L., Fall M., et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society // Neurourol Urodyn. 2002. Vol. 21, N. 2. P. 167–178. doi: 10.1002/nau.10052

[3] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. doi: 10.1016/j.eururo.2006.09.0193

[4] Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study // Eur Urol. 2006. Vol. 50, N. 6. P. 1306–1314. doi: 10.1016/j.eururo.2006.09.0193

[5] Kuzmin IV. Epidemiological aspects of overactive bladder and urge urinary incontinence. Urology reports (St. Petersburg). 2015;5(3):30–34. EDN: VHUCCH doi: 10.17816/uroved5330-3

[6] Кузьмин И.В. Эпидемиологические аспекты гиперактивного мочевого пузыря и ургентного недержания мочи // Урологические ведомости. 2015. Т. 5, № 3. C. 30–34. EDN: VHUCCH doi: 10.17816/uroved5330-3

[7] Kuzmin IV. Pathogenesis, clinical course and treatment of overactive bladder [dissertation]. Saint Petersburg, 2007. (In Russ.)

[8] Кузьмин И.В. Патогенез, клиническое течение и лечение гиперактивности мочевого пузыря: дис. … доктора мед. наук. Санкт-Петербург, 2007.

[9] Sekido N, Hinotsu S, Kawai K, et al. How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study? Int J Urol. 2006;13(10):1276–1279. doi: 10.1111/j.1442-2042.2006.01558.x

[10] Sekido N., Hinotsu S., Kawai K., et al. How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study? // Int J Urol. 2006. Vol. 13, N. 10. P. 1276–1279. doi: 10.1111/j.1442-2042.2006.01558.x

[11] Peyronnet B, Mironska E, Chapple C, et al. A Comprehensive review of overactive bladder pathophysiology: On the way to tailored treatment. Eur Urol. 2019;75(6):988–1000. doi: 10.1016/j.eururo.2019.02.038

[12] Peyronnet B., Mironska E., Chapple C., et al. A Comprehensive review of overactive bladder pathophysiology: On the way to tailored treatment // Eur Urol. 2019. Vol. 75, N. 6. P. 988–1000. doi: 10.1016/j.eururo.2019.02.038

[13] Thurmond P, Yang J-H, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. Am J Physiol Renal Physiol. 2016;310(8):F738–F743. doi: 10.1152/ajprenal.00333.201521

[14] Thurmond P., Yang J.-H., Azadzoi K.M. LUTS in pelvic ischemia: a new concept in voiding dysfunction // Am J Physiol Renal Physiol. 2016. Vol. 310, N. 8. P. F738–F743. doi: 10.1152/ajprenal.00333.201521

[15] Pinggera G-M, Mitterberger M, Steiner E, et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int. 2008;102(4):470–474. doi: 10.1111/j.1464-410X.2008.07587.x

[16] Pinggera G.-M., Mitterberger M., Steiner E., et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography // BJU Int. 2008. Vol. 102, N. 4. P. 470–474. doi: 10.1111/j.1464-410X.2008.07587.x

[17] Al-Shukri SH, Kuzmin IV, Boriskin AG, et al. Correction of microcirculatory disorders in patients with overactive bladder. Nephrology (Saint Petersburg). 2011;15(1):58–64. EDN: NUDVJN

[18] Аль-Шукри С.Х., Кузьмин И.В., Борискин А.Г., и др. Коррекция нарушений микроциркуляции у больных с гиперактивностью мочевого пузыря // Нефрология. 2011. Т. 15, № 1. С. 58–64. EDN: NUDVJN

[19] Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St. Petersburg). 2021;11(3):241–256. EDN: EIDJOH doi: 10.17816/uroved70710

[20] Шорманов И.С., Соловьев А.С., Тюзиков И.А., Куликов С.В. Анатомо-физиологические и патофизиологические особенности нижних мочевых путей в гендерном и возрастном аспектах // Урологические ведомости. 2021. Т. 11, № 3. C. 241–256. EDN: EIDJOH doi: 10.17816/uroved70710

[21] Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology reports (St. Petersburg). 2022;12(2):127–135. EDN: WNTMZA doi: 10.17816/uroved108475

[22] Шорманов И.С., Куликов С.В., Соловьев А.С. Особенности компенсаторно-адаптационных реакций сосудистого русла мочевого пузыря мужчин пожилого и старческого возраста в условиях гиперплазии предстательной железы // Урологические ведомости. 2022. Т. 12, № 2. С. 127–135. EDN: WNTMZA doi: 10.17816/uroved108475

[23] Chen S-L, Ng S-C, Huang Y-H, Chen G-D. Are patients with bladder oversensitivity different from those with urodynamically proven detrusor overactivity in female overactive bladder syndrome? J Chin Med Assoc. 2017;80(10):644–650. doi: 10.1016/j.jcma.2017.03.009

[24] Chen S.-L., Ng S.-C., Huang Y.-H., Chen G.-D. Are patients with bladder oversensitivity different from those with urodynamically proven detrusor overactivity in female overactive bladder syndrome? // J Chin Med Assoc. 2017. Vol. 80, N. 10. P. 644–650. doi: 10.1016/j.jcma.2017.03.009

[25] Jafari NV, Rohn JL. The urothelium: a multi-faceted barrier against a harsh environment. Mucosal Immunol. 2022;15(6): 1127–1142. doi: 10.1038/s41385-022-00565-0

[26] Jafari N.V., Rohn J.L. The urothelium: a multi-faceted barrier against a harsh environment // Mucosal Immunol. 2022. Vol. 15, N. 6. P. 1127–1142. doi: 10.1038/s41385-022-00565-0

[27] de Groat WC, Yoshimura N. Afferent nerve regulation of bladder function in health and disease. In: Canning B, Spina D, editors. Sensory nerves. Handbook of experimental pharmacology. Vol. 194. Springer, Berlin, Heidelberg, 2009. P. 91–138. doi: 10.1007/978-3-540-79090-7_4

[28] de Groat W.C., Yoshimura N. Afferent nerve regulation of bladder function in health and disease. В кн.: Canning B., Spina D., editors. Sensory nerves. Handbook of experimental pharmacology. Vol. 194. Springer, Berlin, Heidelberg, 2009. P. 91–138. doi: 10.1007/978-3-540-79090-7_4

[29] Spencer NJ, Greenheigh S, Kyloh M, et al. Identifying unique subtypes of spinal afferent nerve endings within the urinary bladder of mice. J Comp Neurol. 2018;526(4):707–720. doi: 10.1002/cne.24362

[30] Spencer N.J., Greenheigh S., Kyloh M., et al. Identifying unique subtypes of spinal afferent nerve endings within the urinary bladder of mice // J Comp Neurol. 2018. Vol. 526, N. 4. P. 707–720. doi: 10.1002/cne.24362

[31] Li Z, Lin D, Luo C, et al. The expression and function of Piezo channels in bladder. Bladder (San Franc). 2023;10:e21200008. doi: 10.14440/bladder.2023.870

[32] Li Z., Lin D., Luo C., et al. The expression and function of Piezo channels in bladder // Bladder (San Franc). 2023. Vol. 10. ID e21200008. doi: 10.14440/bladder.2023.870

[33] Vanneste M, Segal A, Voets T, Everaerts W. Transient receptor potential channels in sensory mechanisms of the lower urinary tract. Nat Rev Urol. 2021;18(3):139–159. doi: 10.1038/s41585-021-00428-6

[34] Vanneste M., Segal A., Voets T., Everaerts W. Transient receptor potential channels in sensory mechanisms of the lower urinary tract // Nat Rev Urol. 2021. Vol. 18, N. 3. P. 139–159. doi: 10.1038/s41585-021-00428-6

[35] Reeh PW, Fischer MJM. Nobel somatosensations and pain. Pfluger Arch – Eur J Physiol. 2022;474(4):405–420. doi: 10.1007/s00424-022-02667-x

[36] Reeh P.W., Fischer M.J.M. Nobel somatosensations and pain // Pfluger Arch — Eur J Physiol. 2022. Vol. 474, N. 4. P. 405–420. doi: 10.1007/s00424-022-02667-x

[37] Coste B, Mathur J, Schmidt M, et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science. 2010;330(6000):55–60. doi: 10.1126/science.1193270

[38] Coste B., Mathur J., Schmidt M., et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels // Science. 2010. Vol. 330, N. 6000. P. 55–60. doi: 10.1126/science.1193270

[39] Dalghi MG, Ruiz WG, Clayton DR, et al. Functional roles for PIEZO1 and PIEZO2 in urothelial mechanotransduction and lower urinary tract interoception. JCI Insight. 2021;6(19):e152984. doi: 10.1172/jci.insight.152984

[40] Dalghi M.G., Ruiz W.G., Clayton D.R., et al. Functional roles for PIEZO1 and PIEZO2 in urothelial mechanotransduction and lower urinary tract interoception // JCI Insight. 2021. Vol. 6, N. 19. ID e152984. doi: 10.1172/jci.insight.152984

[41] Skryma R, Prevarskaya N, Gkika D, Shuba Y. From urgency to frequency: facts and controversies of TRPs in the lower urinary tract. Nat Rev Urol. 2011;8(11):617–630. doi: 10.1038/nrurol.2011.14

[42] Skryma R., Prevarskaya N., Gkika D., Shuba Y. From urgency to frequency: facts and controversies of TRPs in the lower urinary tract // Nat Rev Urol. 2011. Vol. 8, N. 11. P. 617–630. doi: 10.1038/nrurol.2011.14

[43] Miyamoto T, Mochizuki T, Nakagomi H, et al. Functional role for Piezo1 in stretch-evoked Ca2+ Influx and ATP release in urothelial cell cultures. J Biol Chem. 2014;289(23):16565–16575. doi: 10.1074/jbc.M113.528638

[44] Miyamoto T., Mochizuki T., Nakagomi H., et al. Functional role for Piezo1 in stretch-evoked Ca2+ Influx and ATP release in urothelial cell cultures // J Biol Chem. 2014. Vol. 289, N. 23. P. 16565–16575. doi: 10.1074/jbc.M113.528638

[45] Grundy L, Wyndaele JJ, Hashitani H, et al. How does the lower urinary tract contribute to bladder sensation? ICI-RS2023. Neurourol Urodyn. 2023; In Press. doi: 10.1002/nau.25316

[46] Grundy L., Wyndaele J.J., Hashitani H., et al. How does the lower urinary tract contribute to bladder sensation? ICI-RS2023 // Neurourol Urodyn. 2023. In Press. doi: 10.1002/nau.25316

[47] Kaplan SA, Dmochowski R, Cash BD, et al. Systematic review of the relationship between bladder and bowel function: implications for patient management. Int J Clin Pract. 2013;67(3):205–216. doi: 10.1111/ijcp.12028

[48] Kaplan S.A., Dmochowski R., Cash B.D., et al. Systematic review of the relationship between bladder and bowel function: implications for patient management // Int J Clin Pract. 2013. Vol. 67, N. 3. P. 205–216. doi: 10.1111/ijcp.12028

[49] Bunn F, Kirby M, Pinkney E, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 2015;69(2):199–217. doi: 10.1111/ijcp.12518

[50] Bunn F., Kirby M., Pinkney E., et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies // Int J Clin Pract. 2015. Vol. 69, N. 2. P. 199–217. doi: 10.1111/ijcp.12518

[51] Vrijens D, Drossaerts J, van Koeveringe G, et al. Affective symptoms and the overactive bladder — a systematic review. J Psychosom Res. 2015;78(2):95–108. doi: 10.1016/j.jpsychores.2014.11.019

[52] Vrijens D., Drossaerts J., van Koeveringe G., et al. Affective symptoms and the overactive bladder — a systematic review // J Psychosom Res. 2015. Vol. 78, N. 2. P. 95–108. doi: 10.1016/j.jpsychores.2014.11.019

[53] Yoshimura N, Ogawa T, Miyazato M, et al. Neural mechanisms underlying lower urinary tract dysfunction. Korean J Urol. 2014;55(2):81–90. doi: 10.4111/kju.2014.55.2.81

[54] Yoshimura N., Ogawa T., Miyazato M., et al. Neural mechanisms underlying lower urinary tract dysfunction // Korean J Urol. 2014. Vol. 55, N. 2. P. 81–90. doi: 10.4111/kju.2014.55.2.81

[55] Gao Z, Liu Y, Zhang L, et al. Nociceptor neurons are involved in the host response to escherichia coli urinary tract infections. J Inflamm Res. 2022;15:3337–3353. doi: 10.2147/JIR.S356960

[56] Gao Z., Liu Y., Zhang L., et al. Nociceptor neurons are involved in the host response to escherichia coli urinary tract infections // J Inflamm Res. 2022. Vol. 15. P. 3337–3353. doi: 10.2147/JIR.S356960

[57] Javan Balegh Marand A, Baars C, Heesakkers J, et al. Differences in the urinary microbiome of patients with overactive bladder syndrome with and without detrusor overactivity on urodynamic measurements. Life (Basel). 2023;13(5):1199. doi: 10.3390/life13051199

[58] Javan Balegh Marand A., Baars C., Heesakkers J., et al. Differences in the urinary microbiome of patients with overactive bladder syndrome with and without detrusor overactivity on urodynamic measurements // Life (Basel). 2023. Vol. 13, N. 5. ID 1199. doi: 10.3390/life13051199

[59] Pillalamarri N, Shalom DF, Pilkinton ML, et al. Inflammatory urinary cytokine expression and quality of life in patients with overactive bladder. Female Pelvic Med Reconstr Surg. 2018;24(6):449–453. doi: 10.1097/spv.0000000000000492

[60] Pillalamarri N., Shalom D.F., Pilkinton M.L., et al. Inflammatory urinary cytokine expression and quality of life in patients with overactive bladder // Female Pelvic Med Reconstr Surg. 2018. Vol. 24, N. 6. P. 449–453. doi: 10.1097/spv.0000000000000492

[61] Farhan B, Chang H, Ahmed A, et al. Characterisation of urinary monocyte chemoattractant protein 1: potential biomarker for patients with overactive bladder. Arab J Urol. 2019;17(1):58–60. doi: 10.1080/2090598x.2019.1589932

[62] Farhan B., Chang H., Ahmed A., et al. Characterisation of urinary monocyte chemoattractant protein 1: potential biomarker for patients with overactive bladder // Arab J Urol. 2019. Vol. 17, N. 1. P. 58–60. doi: 10.1080/2090598x.2019.1589932

[63] Ghoniem G, Farhan B, Csuka D, Zaldivar F. Potential role of monocyte chemoattractant protein-1 in monitoring disease progression and response to treatment in overactive bladder patients. Int Neurourol J. 2020;24(4):341–348. doi: 10.5213/inj.2040366.183

[64] Ghoniem G., Farhan B., Csuka D., Zaldivar F. Potential role of monocyte chemoattractant protein-1 in monitoring disease progression and response to treatment in overactive bladder patients // Int Neurourol J. 2020. Vol. 24, N. 4. P. 341–348. doi: 10.5213/inj.2040366.183

[65] Kullmann FA, Clayton DR, Ruiz WG, et al. Urothelial proliferation and regeneration after spinal cord injury. Am J Physiol Renal Physiol. 2017;313(1):F85–F102. doi: 10.1152/ajprenal.00592.2016

[66] Kullmann F.A., Clayton D.R., Ruiz W.G., et al. Urothelial proliferation and regeneration after spinal cord injury // Am J Physiol Renal Physiol. 2017. Vol. 313, N. 1. P. F85–F102. doi: 10.1152/ajprenal.00592.2016

[67] Butler DSC, Ambite I, Nagy K, et al. Neuroepithelial control of mucosal inflammation in acute cystitis. Sci Rep. 2018;8(1):11015. doi: 10.1038/s41598-018-28634-0

[68] Butler D.S.C., Ambite I., Nagy K., et al. Neuroepithelial control of mucosal inflammation in acute cystitis // Sci Rep. 2018. Vol. 8, N. 1. ID 11015. doi: 10.1038/s41598-018-28634-0

[69] Sun Y, Chai TC. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. Am J Physiol Cell Physiol. 2006;290(1):C27–C34. doi: 10.1152/ajpcell.00552.2004

[70] Sun Y., Chai T.C. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis // Am J Physiol Cell Physiol. 2006. Vol. 290, N. 1. P. C27–C34. doi: 10.1152/ajpcell.00552.2004

[71] Stenqvist J, Winder M, Carlsson T, et al. Urothelial acetylcholine involvement in ATP-induced contractile responses of the rat urinary bladder. Eur J Pharmacol. 2017;809:253–260. doi: 10.1016/j.ejphar.2017.05.023

[72] Stenqvist J., Winder M., Carlsson T., et al. Urothelial acetylcholine involvement in ATP-induced contractile responses of the rat urinary bladder // Eur J Pharmacol. 2017. Vol. 809. P. 253–260. doi: 10.1016/j.ejphar.2017.05.023

[73] Grundy L, Chess-Williams R, Brierley SM, et al. NKA enhances bladder-afferent mechanosensitivity via urothelial and detrusor activation. Am J Physiol Renal Physiol. 2018;315(4):F1174–F1185. doi: 10.1152/ajprenal.00106.2018

[74] Grundy L., Chess-Williams R., Brierley S.M., et al. NKA enhances bladder-afferent mechanosensitivity via urothelial and detrusor activation // Am J Physiol Renal Physiol. 2018. Vol. 315, N. 4. P. F1174–F1185. doi: 10.1152/ajprenal.00106.2018

[75] Slesarevskaya MN, Ignashov YA, Kuzmin IV, Al-Shukri SK. Persistent dysuria in women: etiological diagnostics and treatment. Urology reports (St. Petersburg). 2021;11(3):195–204. EDN: BDUFWQ doi: 10.17816/uroved81948

[76] Слесаревская М.Н., Игнашов Ю.А., Кузьмин И.В., Аль-Шукри С.Х. Стойкая дизурия у женщин: этиологическая диагностика и лечение // Урологические ведомости. 2021. Т. 11, № 3. C. 195–204. EDN: BDUFWQ doi: 10.17816/uroved81948

[77] Kogan MI, Naboka YuL, Ibishev KhS, Gudima IA. Unsterile urine in health human — new paradigm in medicine. Urologiia. 2014;(5): 48–52. EDN: TFDOIP

[78] Коган М.И., Набока Ю.Л., Ибишев Х.С., Гудима И.А. Нестерильность мочи здорового человека — новая парадигма в медицине // Урология. 2014. № 5. С. 48–52. EDN: TFDOIP

[79] Slesarevskaya MN, Kuzmin IV, Zhumadillayev KG, et al. Microbiome and urine microbiota: modern concepts and gender features. Urology reports (St. Petersburg). 2022;12(2):157–165. EDN: VOVNVA doi: 10.17816/uroved109278

[80] Слесаревская М.Н., Кузьмин И.В., Жумадиллаев К.Г., и др. Микробиом и микробиота мочи: современные представления и гендерные особенности // Урологические ведомости. 2022. Т. 12, № 2. C. 157–165. EDN: VOVNVA doi: 10.17816/uroved109278

[81] Ackerman AL, Chai TC. The bladder is not sterile: an update on the urinary microbiome. Curr Bladder Dysfunct Rep. 2019;14(4): 331–341. doi: 10.1007/s11884-019-00543-6

[82] Ackerman A.L., Chai T.C. The bladder is not sterile: an update on the urinary microbiome // Curr Bladder Dysfunct Rep. 2019. Vol. 14, N. 4. P. 331–341. doi: 10.1007/s11884-019-00543-6

[83] Kass EH. Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary antiseptic. AMA Arch Intern Med. 1957;100(5):709–714. doi: 10.1001/archinte.1957.00260110025004

[84] Kass E.H. Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary antiseptic // AMA Arch Intern Med. 1957. Vol. 100, N. 5. P. 709–714. doi: 10.1001/archinte.1957.00260110025004

[85] Perepanova TS, Kozlov RS, Rudnov VA, et al. Antimicrobial therapy and prophylaxis of kidney, urinary tract and male genital infections. Federal clinical recommendations. Moscow, 2022. 126 p. (In Russ.)

[86] Перепанова Т.С., Козлов Р.С., Руднов В.А., и др. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. Москва, 2022. 126 с.

[87] Bonkat G, Bartoletti R, Bruyere F, et al. EAU Guideline of urological infections. European Association of Urology, 2022.

[88] Bonkat G., Bartoletti R., Bruyere F., et al. EAU Guideline of urological infections. European Association of Urology, 2022.

[89] Kshatriya R, Sathiananthamoorthy S, Ismail S, et al. Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms. J Clin Microbiol. 2013;51(7):2054–2062. doi: 10.1128/jcm.03314-12

[90] Kshatriya R., Sathiananthamoorthy S., Ismail S., et al. Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms // J Clin Microbiol. 2013. Vol. 51, N. 7. P. 2054–2062. doi: 10.1128/jcm.03314-12

[91] Pearce MM, Hilt EE, Rosenfeld AB, et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. MBio. 2014;5(4):e01283–14. doi: 10.1128/mBio.01283-14

[92] Pearce M.M., Hilt E.E., Rosenfeld A.B., et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence // MBio. 2014. Vol. 5, N. 4. ID e01283–14. doi: 10.1128/mBio.01283-14

[93] Gill K, Horsley H, Swamy S, et al. A prospective observational study of urinary cytokines and inflammatory response in patients with overactive bladder syndrome. BMC Urol. 2021;21(1):39. doi: 10.1186/s12894-021-00809-4

[94] Gill K., Horsley H., Swamy S., et al. A prospective observational study of urinary cytokines and inflammatory response in patients with overactive bladder syndrome // BMC Urol. 2021. Vol. 21, N. 1. ID 39. doi: 10.1186/s12894-021-00809-4

[95] Thomas-White KJ, Hilt EE, Fok C, et al. Incontinence medication response relates to the female urinary microbiota. Int Urogynecol J. 2016;27:723–733. doi: 10.1007/s00192-015-2847-x

[96] Thomas-White K.J., Hilt E.E., Fok C., et al. Incontinence medication response relates to the female urinary microbiota // Int Urogynecol J. 2016. Vol. 27. P. 723–733. doi: 10.1007/s00192-015-2847-x

[97] Khan Z, Healey GD, Paravati R, et al. Chronic urinary infection in overactive bladder syndrome: a prospective, blinded case control study. Front Cell Infect Microbiol. 2021;11:752275. doi: 10.3389/fcimb.2021.752275

[98] Khan Z., Healey G.D., Paravati R., et al. Chronic urinary infection in overactive bladder syndrome: a prospective, blinded case control study // Front Cell Infect Microbiol. 2021. Vol. 11. ID 752275. doi: 10.3389/fcimb.2021.752275

[99] Cheng Y, Chen Z, Gawthorne JA, et al. Detection of intracellular bacteria in exfoliated urothelial cells from women with urge incontinence. Pathog Dis. 2016;74(7):ftw067. doi: 10.1093/femspd/ftw067

[100] Cheng Y., Chen Z., Gawthorne J.A., et al. Detection of intracellular bacteria in exfoliated urothelial cells from women with urge incontinence // Pathog Dis. 2016. Vol. 74, N. 7. ID ftw067. doi: 10.1093/femspd/ftw067

[101] Justice SS, Hunstad DA, Seed PC, Hultgren SJ. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. PNAS USA. 2006;103(52):19884–19889. doi: 10.1073/pnas.0606329104

[102] Justice S.S., Hunstad D.A., Seed P.C., Hultgren S.J. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection // PNAS USA. 2006. Vol. 103, N. 52. P. 19884–19889. doi: 10.1073/pnas.0606329104

[103] Ognenovska S, Chen Z, Mukerjee C, et al. Bacterial colonization of bladder urothelial cells in women with refractory detrusor overactivity: the effects of antibiotic therapy. Pathog Dis. 2021;79(6):ftab031. doi: 10.1093/femspd/ftab031

[104] Ognenovska S., Chen Z., Mukerjee C., et al. Bacterial colonization of bladder urothelial cells in women with refractory detrusor overactivity: the effects of antibiotic therapy // Pathog Dis. 2021. Vol. 79, N. 6. ID ftab031. doi: 10.1093/femspd/ftab031

[105] Mansfield KJ, Chen Z, Moore KH, Grundy L. Urinary tract infection in overactive bladder: An update on pathophysiological mechanisms. Front Physiol. 2022;13:886782. doi: 10.3389/fphys.2022.886782

[106] Mansfield K.J., Chen Z., Moore K.H., Grundy L. Urinary tract infection in overactive bladder: An update on pathophysiological mechanisms // Front Physiol. 2022. Vol. 13. ID 886782. doi: 10.3389/fphys.2022.886782

[107] Gill K, Kang R, Sathiananthamoorthy S, et al. A blinded observational cohort study of the Microbiological Ecology Associated with pyuria and overactive bladder symptoms. Int Urogynecol J. 2018;29(10):1493–1500. doi: 10.1007/s00192-018-3558-x

[108] Gill K., Kang R., Sathiananthamoorthy S., et al. A blinded observational cohort study of the Microbiological Ecology Associated with pyuria and overactive bladder symptoms // Int Urogynecol J. 2018. Vol. 29, N. 10. P. 1493–1500. doi: 10.1007/s00192-018-3558-x

[109] Grundy L, Caldwell A, Lumsden A, et al. Experimentally induced bladder permeability evokes bladder afferent hypersensitivity in the absence of inflammation. Front Neurosci. 2020;14:590871. doi: 10.3389/fnins.2020.590871

[110] Grundy L., Caldwell A., Lumsden A., et al. Experimentally induced bladder permeability evokes bladder afferent hypersensitivity in the absence of inflammation // Front Neurosci. 2020. Vol. 14. ID 590871. doi: 10.3389/fnins.2020.590871

[111] Brierley SM, Goh KGK, Sullivan MJ, et al. Innate immune response to bacterial urinary tract infection sensitises high-threshold bladder afferents and recruits silent nociceptors. Pain. 2020;161(1):202–210. doi: 10.1097/j.pain.0000000000001692

[112] Brierley S.M., Goh K.G.K., Sullivan M.J., et al. Innate immune response to bacterial urinary tract infection sensitises high-threshold bladder afferents and recruits silent nociceptors // Pain. 2020. Vol. 161, N. 1. P. 202–210. doi: 10.1097/j.pain.0000000000001692

[113] Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian medical inquiry. 2021;5(5): 273–279. EDN: WABDWM doi: 10.32364/2587-6821-2021-5-5-273-279

[114] Кузьмин И.В., Кузьмина С.В. Антихолинергическая терапия гиперактивного мочевого пузыря: практические аспекты // РМЖ. Медицинское обозрение. 2021. Т. 5, № 5. С. 273–279. EDN: WABDWM doi: 10.32364/2587-6821-2021-5-5-273-279

[115] Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK Experience. BJU Int. 2012;110(11):1767–1774. doi: 10.1111/j.1464-410x.2012.11023.x

[116] Wagg A., Compion G., Fahey A., Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK Experience // BJU Int. 2012. Vol. 110, N. 11. P. 1767–1774. doi: 10.1111/j.1464-410x.2012.11023.x

[117] Kim TH, Lee K-S. Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol. 2016;57(2):84–93. doi: 10.4111/icu.2016.57.2.84

[118] Kim T.H., Lee K.-S. Persistence and compliance with medication management in the treatment of overactive bladder // Investig Clin Urol. 2016. Vol. 57, N. 2. P. 84–93. doi: 10.4111/icu.2016.57.2.84

[119] Yeowell G, Smith P, Nazir J, et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11):e021889. doi: 10.1136/bmjopen-2018-021889

[120] Yeowell G., Smith P., Nazir J., et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review // BMJ Open. 2018. Vol. 8, N. 11. ID e021889. doi: 10.1136/bmjopen-2018-021889

[121] Kuzmin IV, Slesarevskaya MN, Amdiy RE, et al. Long-term botulinum therapy for overactive bladder: myths and reality. Urology reports (St. Petersburg). 2022;12(1):71–84. EDN: OYTVRD doi: 10.17816/uroved104335

[122] Кузьмин И.В., Слесаревская М.Н., Амдий Р.Э., и др. Длительная ботулинотерапия гиперактивного мочевого пузыря: мифы и реальность // Урологические ведомости. 2022. Т. 12, № 1. C. 71–84. EDN: OYTVRD doi: 10.17816/uroved104335

[123] Kim A, Lee K-S, Kim TB, et al. Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment. Investig Clin Urol. 2017;58(1):42–47. doi: 10.4111/icu.2017.58.1.42

[124] Kim A., Lee K.-S., Kim T.B., et al. Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment // Investig Clin Urol. 2017. Vol. 58, N. 1. P. 42–47. doi: 10.4111/icu.2017.58.1.42

[125] Morris AR, Westbrook JI, Moore KH. A longitudinal study over 5 to 10 years of clinical outcomes in women with idiopathic detrusor overactivity. BJOG. Int J Obstet Gynecol. 2008;115(2):239–246. doi: 10.1111/j.1471-0528.2007.01527.x

[126] Morris A.R., Westbrook J.I., Moore K.H. A longitudinal study over 5 to 10 years of clinical outcomes in women with idiopathic detrusor overactivity // BJOG. Int J Obstet Gynecol. 2008. Vol. 115, N. 2. P. 239–246. doi: 10.1111/j.1471-0528.2007.01527.x

[127] Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clinical gerontology. 2021;27(11–12):21–34. EDN: ZHMMTR doi: 10.26347/1607-2499202111-12021-034

[128] Кузьмин И.В., Слесаревская М.Н. Антихолинергическая терапия гиперактивного мочевого пузыря: геронтологические аспекты // Клиническая геронтология. 2021. Т. 27, № 11–12. С. 21–34. EDN: ZHMMTR doi: 10.26347/1607-2499202111-12021-034

[129] Kuzmin IV. Personalized approach to pharmacotherapy of overactive bladder. Urology reports (St. Petersburg). 2023;13(3):267–282. EDN: XJVYUG doi: 10.17816/uroved569404

[130] Кузьмин И.В. Персонифицированный подход к фармакотерапии гиперактивного мочевого пузыря // Урологические ведомости. 2023. Т. 13, № 3. C. 267–282. EDN: XJVYUG doi: 10.17816/uroved569404

[131] Tsubouchi K, Arima H, Abe M, et al. Effect of pharmacotherapy for overactive bladder on the incidence of and factors related to urinary tract infection: A systematic review and meta-analysis. J Urol. 2023;209(4):665–674. doi: 10.1097/JU.0000000000003209

[132] Tsubouchi K., Arima H., Abe M., et al. Effect of pharmacotherapy for overactive bladder on the incidence of and factors related to urinary tract infection: A systematic review and meta-analysis // J Urol. 2023. Vol. 209, N. 4. P. 665–674. doi: 10.1097/JU.0000000000003209

[133] Kshatriya RK, Brackenridge A, Horsley L, et al. The antibiotic treatment of OAB cohort. 36th Annual IUGA Meeting, Lisbon, Portugal, 28 June – 2 July 2011. Int Urogynecol J. 2011;22(1):1–195. doi: 10.1007/s00192-011-1434-z

[134] Kshatriya R.K., Brackenridge A., Horsley L., et al. The antibiotic treatment of OAB cohort. 36th Annual IUGA Meeting, Lisbon, Portugal, 28 June – 2 July 2011 // Int Urogynecol J. 2011. Vol. 22, N. 1. P. 1–195. doi: 10.1007/s00192-011-1434-z

[135] Vijaya G, Cartwright R, Derpapas A, et al. Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder. Int Urogynecol J. 2013;24(9): 1523–1528. doi: 10.1007/s00192-012-2038-y

[136] Vijaya G., Cartwright R., Derpapas A., et al. Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder // Int Urogynecol J. 2013. Vol. 24, N. 9. P. 1523–1528. doi: 10.1007/s00192-012-2038-y

[137] Chen Z, Moore KH, Mansfield KJ, et al. Effect of antibiotics on urine leakage in women with refractory detrusor overactivity: A phase IIb randomized trial. Neurourol Urodynamics. 2021;40(1): 158–167. doi: 10.1002/nau.24525

[138] Chen Z., Moore K.H., Mansfield K.J., et al. Effect of antibiotics on urine leakage in women with refractory detrusor overactivity: A phase IIb randomized trial // Neurourol Urodynamics. 2021. Vol. 40, N. 1. P. 158–167. doi: 10.1002/nau.24525

[139] Chen Z, Ognenovska S, Sluyter R, et al. Urinary cytokines in women with refractory detrusor overactivity: A longitudinal study of rotating antibiotic versus placebo treatment. PLoS One. 2021;16(3): e0247861. doi: 10.1371/journal.pone.0247861

[140] Chen Z., Ognenovska S., Sluyter R., et al. Urinary cytokines in women with refractory detrusor overactivity: A longitudinal study of rotating antibiotic versus placebo treatment // PLoS One. 2021. Vol. 16, N. 3. ID e0247861. doi: 10.1371/journal.pone.0247861

[141] Moore M, Trill J, Simpson C, et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a Factorial randomized trial. Clin Microbiol Infect. 2019;25(8):973–980. doi: 10.1016/j.cmi.2019.01.011

[142] Moore M., Trill J., Simpson C., et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a Factorial randomized trial // Clin Microbiol Infect. 2019. Vol. 25, N. 8. P. 973–980. doi: 10.1016/j.cmi.2019.01.011

[143] Loubet P, Ranfaing J, Dinh A, et al. Alternative therapeutic options to antibiotics for the treatment of urinary tract infections. Front Microbiol. 2020;11:1509. doi: 10.3389/fmicb.2020.01509

[144] Loubet P., Ranfaing J., Dinh A., et al. Alternative therapeutic options to antibiotics for the treatment of urinary tract infections // Front Microbiol. 2020. Vol. 11. ID 1509. doi: 10.3389/fmicb.2020.01509

[145] Shormanov IS, Solovyov AS, Chirkov IA, et al. Opportunities of drugs based on D-mannose and herbal components in the treatment and prevention of recurrent lower urinary tract infections in women. Urology reports (St. Petersburg). 2022;12(1):13–20. EDN: XEEZQJ doi: 10.17816/uroved84084

[146] Шорманов И.С., Соловьев А.С., Чирков И.А., и др. Возможности препаратов на основе D-маннозы и растительных компонентов в лечении и профилактике рецидивирующих инфекций нижних мочевых путей у женщин // Урологические ведомости. 2022. Т. 12, № 1. С. 13–20. EDN: XEEZQJ doi: 10.17816/uroved84084

[147] Kulchavenya EV, Neymark AI, Tcukanov AYu, et al. Combined therapy of patients with recurrent cystitis using a complex of natural antimicrobial peptides and cytokines: first results. Urologiia. 2022;(6):47–55. EDN: PNFBXD doi: 10.18565/urology.2022.6.47-55

[148] Кульчавеня Е.В., Неймарк А.И., Цуканов А.Ю., и др. Комбинированная терапия больных рецидивирующим циститом с применением комплекса природных антимикробных пептидов и цитокинов: первые результаты // Урология. 2022. № 6. С. 47–55. EDN: PNFBXD doi: 10.18565/urology.2022.6.47-55

[149] Kuzmin IV, Slesarevskaya MN, Al-Shukri SH. Antiadhesive strategy for non-antibacterial prophylaxis of recurrent lower urinary tract infections. Urologiia. 2021;(3):5–12. EDN: RAHHLU doi: 10.18565/urology.2021.3:5-12

[150] Кузьмин И.В., Слесаревская М.Н., Аль-Шукри С.Х. Антиадгезивная стратегия неантибактериальной профилатики рецидивирующей инфекции нижних мочевыводящих путей // Урология. 2021. № 3. С. 5–12. EDN: RAHHLU doi: 10.18565/urology.2021.3:5-12

[151] Slesarevskaya MN, Kuzmin IV, Al-Shukri SH. Infection of the lower urinary tract: new possibilities of herbal medicine. Urologiia. 2022;(2):103–112. EDN: JFVFCF doi: 10.18565/urology.2022.2.103-112

[152] Слесаревская М.Н., Кузьмин И.В., Аль-Шукри С.Х. Инфекция нижних мочевыводящих путей: новые возможности фитотерапии // Урология. 2022. № 2. С. 103–112. EDN: JFVFCF doi: 10.18565/urology.2022.2.103-112

[153] Cardozo LD, Stanton SL. A comparison between bromocriptine and indomethacin in the treatment of detrusor instability. J Urol. 1980;123(3):399–401. doi: 10.1016/s0022-5347(17)55955-8

[154] Cardozo L.D., Stanton S.L. A comparison between bromocriptine and indomethacin in the treatment of detrusor instability // J Urol. 1980. Vol. 123, N. 3. P. 399–401. doi: 10.1016/s0022-5347(17)55955-8

[155] Delaere KPJ, Debruyne FMJ, Moonen WA. The Use of Indomethacin in the treatment of idiopathic bladder instability. Urol Int. 1981;36(2):124–127. doi: 10.1159/000280402

[156] Delaere K.P.J., Debruyne F.M.J., Moonen W.A. The Use of Indomethacin in the treatment of idiopathic bladder instability // Urol Int. 1981. Vol. 36, N. 2. P. 124–127. doi: 10.1159/000280402

[157] Kuhn HW, Hreha TN, Hunstad DA. Immune defenses in the urinary tract. Trends Immunol. 2023;44(9):701–711. doi: 10.1016/j.it.2023.07.001

[158] Kuhn H.W., Hreha T.N., Hunstad D.A. Immune defenses in the urinary tract // Trends Immunol. 2023. Vol. 44, N. 9. P. 701–711. doi: 10.1016/j.it.2023.07.001

[159] Klein Wolterink RGJ, Wu GS, Chiu IM, Veiga-Fernandes H. Neuroimmune Interactions in peripheral organs. Annu Rev Neurosci. 2022;45:339–360. doi: 10.1146/annurev-neuro-111020-105359

[160] Klein Wolterink R.G.J., Wu G.S., Chiu I.M., Veiga-Fernandes H. Neuroimmune Interactions in peripheral organs // Annu Rev Neurosci. 2022. Vol. 45. P. 339–360. doi: 10.1146/annurev-neuro-111020-105359

[161] Rosenthal M. Effect of a bacterial extract on cellular and humoral immune responses in humans. J Immunopharmacol. 1986;8(3):315–325. doi: 10.3109/08923978609026492

[162] Rosenthal M. Effect of a bacterial extract on cellular and humoral immune responses in humans // J Immunopharmacol. 1986. Vol. 8, N. 3. P. 315–325. doi: 10.3109/08923978609026492

[163] Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent tract infections with immunoactive E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002;19(9):451–456. doi: 10.1016/S0924-8579(02)00106-1

[164] Bauer H.W., Rahlfs V.W., Lauener P.A., Blessmann G.S. Prevention of recurrent tract infections with immunoactive E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies // Int J Antimicrob Agents. 2002. Vol. 19, N. 9. P. 451–456. doi: 10.1016/S0924-8579(02)00106-1

[165] Naber KG, Cho Y-H, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009;33(2):111–119. doi: 10.1016/j.ijantimicag.2008.08.011

[166] Naber K.G., Cho Y.-H., Matsumoto T., Schaeffer A.J. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis // Int J Antimicrob Agents. 2009. Vol. 33, N. 2. P. 111–119. doi: 10.1016/j.ijantimicag.2008.08.011

[167] Brodie A, El-Taji O, Jour I, et al. A Retrospective study of immunotherapy treatment with Uro-Vaxom (OM-89®) for prophylaxis of recurrent urinary tract infections. Curr Urol. 2020;14(3):130–134. doi: 10.1159/000499248

[168] Brodie A., El-Taji O., Jour I., et al. A Retrospective study of immunotherapy treatment with Uro-Vaxom (OM-89®) for prophylaxis of recurrent urinary tract infections // Curr Urol. 2020. Vol. 14, N. 3. P. 130–134. doi: 10.1159/000499248

[169] Loran OB, Kogan MI, Sinjakova LA, et al. Rational therapy for recurrent infections of the lower urinary tract. The results of a prospective observational program to assess the effectiveness and safety of Ceforal®, Solutab® and Uro-Vaksom® in patients with recurrent uncomplicated lower urinary tract infections (FLORA). Urologiia. 2015;(4):11–18. EDN: UMTAPX

[170] Лоран О.Б., Коган М.И., Синякова Л.А., и др. Рациональная терапия рецидивирующих инфекций нижних мочевыводящих путей. Результаты проспективной наблюдательной программы по оценке эффективности и безопасности применения препаратов Цефорал® Солютаб® и Уро-Ваксом® у пациенток с рецидивирующими неосложненными инфекциями нижних мочевыводящих путей (FLORA) // Урология. 2015. № 4. С. 11–18. EDN: UMTAPX

[171] Ermakova EI. The role of vaccine prophylaxis in the treatment of recurrent urinary tract infections in menopausal women. Medical Council. 2021;(4):129–134. EDN: UHPWOP doi: 10.21518/2079-701X-2021-4-129-134

[172] Ермакова Е.И. Роль вакцинопрофилактики в терапии рецидивирующих инфекций мочевых путей у женщин в менопаузе // Медицинский совет. 2021. № 4. С. 129–134. EDN: UHPWOP doi: 10.21518/2079-701X-2021-4-129-134

[173] Prattley S, Geraghty R, Moore M, Somani BK. Role of vaccines for recurrent urinary tract infections: a systematic review. Eur Urol Focus. 2020;6(3):593–604. doi: 10.1016/j.euf.2019.11.002

[174] Prattley S., Geraghty R., Moore M., Somani B.K. Role of vaccines for recurrent urinary tract infections: a systematic review // Eur Urol Focus. 2020. Vol. 6, N. 3. P. 593–604. doi: 10.1016/j.euf.2019.11.002

[175] Akhmatova NK, Khomenkov VG, Volkova EV, et al. Bacterial lysates of Escherichia coli stimulate production of defensins by peripheral blood neutrophils. Journal of microbiology, epidemiology and immunobiology. 2016;(4):50–55. EDN: ZRJDLJ doi: 10.36233/0372-9311-2016-4-50-55

[176] Ахматова Н.К., Хоменков В.Г., Волкова Е.В., и др. Бактериальные лизаты Escherichia coli стимулируют продукцию дефенсинов нейтрофилами периферической крови // Журнал микробиологии, эпидемиологии и иммунобиологии. 2016. № 4. С. 50–55. EDN: ZRJDLJ doi: 10.36233/0372-9311-2016-4-50-55

RIGHTS & PERMISSIONS

Eco-Vector